Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 4/20 | 1.00 |
| ▸ | GCLC | P48506 | 1/20 | 0.71 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.69 |
| ▸ | GRM8 | O00222 | 1/20 | 0.68 |
| ▸ | GRM6 | O15303 | 1/20 | 0.68 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.68 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.68 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15278193 | 1.00 | FOLH1 (1.00) | FOLH1GCLCGRM3GRM8GRM6 | |
| SCHEMBL2742761 | 0.89 | FOLH1 (0.81) | FOLH1GCLCGRM3GRM8GRM6 | |
| SCHEMBL14155152 | 0.88 | FOLH1 (0.78) | FOLH1GCLCGRM3GRM8GRM6 | |
| SCHEMBL15866063 | 0.87 | FOLH1 (0.76) | FOLH1GCLCGRM3GRM8GRM6 | |
| SCHEMBL4095796 | 0.85 | FOLH1 (0.74) | FOLH1GCLCGRM8GRM6GRM7 | |
| SCHEMBL4088761 | 0.85 | FOLH1 (0.74) | FOLH1GCLCGRM8GRM6GRM7 | |
| SCHEMBL16508250 | 0.85 | FOLH1 (0.74) | FOLH1GCLCGRM3GRM8GRM6 | |
| SCHEMBL20529841 | 0.84 | GRM3 (0.81) | FOLH1GRM3NAALAD2 | |
| SCHEMBL5051325 | 0.84 | GRM3 (0.81) | FOLH1GRM3NAALAD2 | |
| SCHEMBL14927201 | 0.84 | GCLC (0.82) | FOLH1GCLCGRM8GRM6GRM7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125959-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS AS DIAGNOSTIC AND RADIONUCLIDE THERAPEUTIC AGENTS | FIVE ELEVEN PHARMA INC (US) | 2022-04-28 | — | — | US | disclosed |
| EP-3397968-B1 | UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY | FIVE ELEVEN PHARMA INC (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20210188979-A1 | Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods of Making and Using Same | PFIZER INC. (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210177857-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING THE SAME | PFIZER INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-10952972-B2 | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same | PFIZER INC. (US) | 2021-03-23 | — | — | US | disclosed |
| WO-2020220023-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS AS DIAGNOSTIC AND RADIONUCLIDE THERAPEUTIC AGENTS | FIVE ELEVEN PHARMA INC. (US) | 2020-10-29 | — | — | WO | disclosed |
| EP-3511019-B1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | PFIZER (US) | 2020-10-14 | — | — | EP | disclosed |
| US-10688200-B2 | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy | FIVE ELEVEN PHARMA INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20200093827-A1 | Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same | PFIZER INC. (US) | 2020-03-26 | — | — | US | disclosed |
| EP-2774608-B1 | Drug loaded polymeric nanoparticles and methods of making and using same | PFIZER (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20110274759-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | PFIZER INC. | 2011-11-10 | — | — | US | disclosed |
| US-20110237686-A1 | FORMULATIONS AND METHODS OF USE | CERULEAN PHARMA INC (US) | 2011-09-29 | — | — | US | disclosed |
| US-20100068286-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | PFIZER INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100068285-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | PFIZER INC. | 2010-03-18 | — | — | US | disclosed |
| WO-2010005721-A2 | DRUG LOADED POLYMERIC NANOPARTICLES AND METHODS OF MAKING AND USING SAME | BIND BIOSCIENCES, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010005740-A2 | METHODS FOR THE PREPARATION OF TARGETING AGENT FUNCTIONALIZED DIBLOCK COPOLYMERS FOR USE IN FABRICATION OF THERAPEUTIC TARGETED NANOPARTICLES | BIND BIOSCIENCES, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010005723-A2 | DRUG LOADED POLYMERIC NANOPARTICLES AND METHODS OF MAKING AND USING SAME | BIND BIOSCIENCES, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2008121949-A1 | CANCER CELL TARGETING USING NANOPARTICLES | BIND BIOSCIENCES, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20080175789-A1 | Modified PSMA ligands and uses related thereto | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080175789-A1 | Modified PSMA ligands and uses related thereto | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110274759-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | LDHA, LDHB, LPXN | FOLH1 177/4885GCLC 2702/4885GRM3 3796/4885 |
| US-20100068285-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | CD47, LPXN, CD44 | FOLH1 173/4885GCLC 2910/4885GRM3 3970/4885 |
| US-10688200-B2 | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy | KLK3, FOLH1, UTS2R | FOLH1 2/4885GCLC 2327/4885GRM3 929/4885 |
| US-20080175789-A1 | Modified PSMA ligands and uses related thereto | FOLH1, KLK3, PSMA1 | FOLH1 1/4885GCLC 1460/4885GRM3 1264/4885 |
| US-20210188979-A1 | Therapeutic Nanoparticles Comprising A Therapeutic Agent And Methods of Making and Using Same | CD47, CD274, PDCD1 | FOLH1 8/4885GCLC 3358/4885GRM3 1415/4885 |
| US-10952972-B2 | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same | CTSA, GAA, EEA1 | FOLH1 135/4885GCLC 2788/4885GRM3 3516/4885 |
| US-20220125959-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS AS DIAGNOSTIC AND RADIONUCLIDE THERAPEUTIC AGENTS | KLK3, FOLH1, PSMA1 | FOLH1 2/4885GCLC 2976/4885GRM3 1626/4885 |
| US-20200093827-A1 | Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same | MTHFD1, TYMP, FPGS | FOLH1 51/4885GCLC 1458/4885GRM3 3406/4885 |
| US-20100068286-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | LDHA, LDHB, LPXN | FOLH1 177/4885GCLC 2702/4885GRM3 3796/4885 |
| US-20110237686-A1 | FORMULATIONS AND METHODS OF USE | LPXN, LIPA, CHMP4B | FOLH1 978/4885GCLC 4030/4885GRM3 2491/4885 |
| US-20210177857-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING THE SAME | TP53, HNRNPH3, VHL | FOLH1 336/4885GCLC 2419/4885GRM3 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.